Scienza e Tecnologia
Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets
For the past over six years, Dr. Egros has played an integral role in Lupin, leading businesses across both Growth and Developed markets. His extensive cross-border experience as well as successful experience with acquisitions, divestitures, joint ventures and partnerships will be an asset to Lupin in this new role.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India . The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India , South Africa , and across the Asia Pacific (APAC), Latin America (LATAM), Europe , and the Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue in research and development in FY21.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal|LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/
Vice President & Global Head – Corporate Communications
Email: shwetamunjal@lupin.com
Logo: https://mma.prnewswire.com/media/1158525/lupin_pharmaceuticals_Logo.jpg